Bexarotene


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0003712 Transcription coregulator activity Increases phenotype PMID:35483669
GO:0006641 Triglyceride metabolic process Affects phenotype PMID:32123961
GO:0006915 Apoptotic process Increases phenotype PMID:15781672; PMID:24080207
GO:0008283 Cell population proliferation Increases phenotype PMID:24080207
GO:0008285 Negative regulation of cell population proliferation Increases phenotype PMID:26385866
GO:0016043 Cellular component organization Affects phenotype PMID:35483669
GO:0019432 Triglyceride biosynthetic process Increases phenotype PMID:23292798
GO:0045600 Positive regulation of fat cell differentiation Increases phenotype PMID:25932594
GO:0048386 Positive regulation of retinoic acid receptor signaling pathway Increases phenotype PMID:35483669; PMID:8853895
GO:0048598 Embryonic morphogenesis Decreases phenotype PMID:26385866
GO:0051091 Positive regulation of dna-binding transcription factor activity Affects phenotype PMID:31566444; PMID:8853895
GO:0060487 Lung epithelial cell differentiation Affects phenotype PMID:8853895
GO:1903012 Positive regulation of bone development Increases phenotype PMID:25932594
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.